Developing a Therapeutic Vaccine for the Treatment of Acne Vulgaris

Time: 9:15 am
day: Conference Day One


  • There is clear recognition of the need for new innovative approaches to treat acne vulgaris and improve the patient’s treatment journey and outcomes.
  • Sanofi is developing a therapeutic vaccine based on key antigens from the bacterium Cutibacterium acnes.
  • Pre-clinical data has been generated for the lead vaccine candidates, supporting transition into the clinical evaluation phase of the vaccine.